

ISO 23033:2021 (E)

Biotechnology — Analytical methods — General requirements and considerations for the testing and characterization of cellular therapeutic products

Contents

	Foreword
	Introduction
1	Scope
2	Normative references
3	Terms and definitions
4	Cellular starting materials
5	Design of fit for purpose analytical methods for evaluating quality attributes
5.1	General concepts
5.2	Approach to analytical method design
5.3	Defining quality attributes by considering components of a cellular therapeutic product
5.4	Design of a matrix of analytical methods
5.5	Design of a fit for purpose analytical method
5.6	Selection of instruments
5.7	Instrument qualification and maintenance
5.8	Managing sources of measurement variability for cell measurements
5.8.1	General
5.8.2	Sampling and sample preparation
5.8.3	Reference materials
5.8.4	Analytical reagents
5.9	Documentation of procedure
6	Analytical method qualification, validation and continued verification
6.1	General
6.2	Analytical method qualification
6.3	Analytical method validation and continued verification
6.3.1	Validation
6.3.2	Continued verification
6.4	Test method performance criteria
7	Testing of cellular therapeutic products
7.1	Considerations for specifications and release criteria for cellular therapeutic products
7.1.1	General
7.1.2	Considerations for release criteria for the final cellular therapeutic product
7.2	General requirements for the testing of the cellular therapeutic product
7.3	Testing to evaluate identity of a cellular therapeutic product
7.4	Testing to evaluate cell counts within cellular therapeutic products
7.5	Testing to evaluate viability of cells within a cellular therapeutic product
7.6	Testing to evaluate potency of a cellular therapeutic product
7.6.1	General
7.6.2	Importance of potency as a CQA
7.6.3	Assessment of potency
7.6.4	Requirements for analytical methods that evaluate potency
7.6.5	Design of analytical methods that evaluate potency
7.6.6	Considerations for analytical methods that evaluate potency
7.7	Testing to evaluate the purity of cellular therapeutic products
7.8	Testing to evaluate microbiological contamination of cellular therapeutic products

7.9	Testing to evaluate stability of cellular therapeutic products
8	Reporting
8.1	General
8.2	General requirements
Annex A	(informative) Establishing a testing strategy for cellular therapeutic products
Annex B	(informative) Examples of potential sources of variability in a cell analytical method

Page count: 35